Geneticists have long been aware that the architecture of common complex diseases varies among ethnicities, but quantifying these differences and their impact on disease prediction accuracy has remained a significant challenge. The current research relies on an extensive genome-wide association study (GWAS) conducted on a Han Chinese cohort derived from the Taiwan Precision Medicine Initiative (TPMI). By comparing these results with those from a European population-based GWAS from the UK Biobank (UKB), the study rigorously evaluates the transethnic genetic-effect correlations that govern polygenic traits and diseases.

One of the central breakthroughs revealed in the paper is the heterogeneous nature of genetic correlation across populations for different traits. For complex diseases such as cholelithiasis, an extraordinarily high transethnic genetic-effect correlation (>0.999) was observed, suggesting almost identical genetic determinants between the Han Chinese and European groups. This finding underscores that certain genetically mediated conditions may possess highly conserved causal variants across human populations, offering opportunities for universal predictive genetic markers.

However, the study also exposes contrasting scenarios. For pervasive metabolic diseases like type 2 diabetes and ischaemic heart disease, while still significantly correlated across populations, the genetic-effect correlations were more moderate—0.829 and 0.756 respectively—suggesting substantial but not complete overlap in genetic architecture. These intermediate correlations imply that while some loci contribute similarly to disease risk among different ancestries, others may be population-specific or exert varying effect sizes.

More strikingly, the genetic correlations drop markedly for diseases such as gout and psoriasis. Gout showed a moderate correlation of 0.616, while psoriasis exhibited only a weak correlation of 0.418, pointing toward distinctly differentiated genetic mechanisms. This sharp decline hints not only at divergent allele frequencies and variant effects but also implicates complex gene-environment interactions and evolutionary histories that uniquely shape disease prevalence and manifestation in different ethnic backgrounds.

These findings have practical consequences for the design and utility of polygenic risk scores. PRS models developed predominantly with European-ancestry datasets often underperform or produce biased risk estimates when applied to non-European populations. The demonstrated variability in cross-population genetic effect sizes renders a “one-size-fits-all” approach ineffective, emphasizing the critical need for ancestry-specific genetic data to refine risk prediction algorithms.

Crucially, the study highlights the disease case numbers within each cohort, underscoring how sample size disparities might influence correlation estimates. For example, the gout case count in TPMI was 24,411, considerably larger than the 3,179 cases in UKB, reflecting differential disease burdens and data availability. Psoriasis cases were 4,166 in TPMI and 2,197 in UKB. Such discrepancies further advocate for tailored cohort construction to yield robust and representative genetic insights.

Technologically, the researchers employed advanced statistical methodologies for cross-population genetic-effect correlation assessment, building upon previous frameworks but extending them to capture subtle allele frequency and linkage disequilibrium differences inherent to the distinct biogeographical groups. This rigorous analytical approach ensures the identification of both shared and unique genetic variants implicated in complex diseases across ancestries.

From an evolutionary biology perspective, understanding these transethnic correlations offers glimpses into historic population divergence, selective pressures, and migration patterns that have sculpted the genetic landscape of chronic diseases. It reveals how natural selection and genetic drift could differentially influence variant distributions, modifying disease susceptibilities in various human populations.

Implications for genetic counseling and public health are profound. Incorporating population-specific PRS can lead to more equitable healthcare by providing precise risk stratification for individuals of Han Chinese descent and potentially other underrepresented groups. This can enhance early disease detection, inform preventive strategies, and optimize personalized treatment plans, thereby narrowing health disparities amplified by Eurocentric genomic research biases.

Moreover, the paper champions the systematic expansion of large-scale genomic databases encompassing diverse ancestries, thus urging the scientific community and funding bodies to invest in global collaborations and inclusive recruitment paradigms. Only through such broadened data representation can polygenic risk prediction achieve accuracy and fairness across the world’s heterogeneous populations.

Looking forward, the study paves the way for integrating multi-omic and environmental data layers with population-specific genetic scores. This multi-dimensional approach promises to unravel even more refined predictors of disease risk and progression, pushing the frontier of precision medicine beyond genetic variants alone.

In conclusion, this seminal work by Chen and colleagues powerfully demonstrates that genetic efficacy in disease prediction necessitates acknowledging and incorporating population-specific genetic architectures. Their comprehensive analysis reinforces the scientific mandate to design polygenic risk scoring frameworks that are culturally and genetically inclusive, revolutionizing genomic medicine by transcending ancestral boundaries.

Subject of Research: Population-specific polygenic risk scores and transethnic genetic-effect correlations in Han Chinese versus European ancestries.

Article Title: Population-specific polygenic risk scores for people of Han Chinese ancestry.

Article References:
Chen, HH., Chen, CH., Hou, MC. et al. Population-specific polygenic risk scores for people of Han Chinese ancestry. Nature (2025). https://doi.org/10.1038/s41586-025-09350-y

Image Credits: AI Generated

In the realm of global genetic research, there remains a significant imbalance in the representation of various ethnic groups. Despite Han Chinese individuals constituting nearly 20% of the world’s population, they have been starkly underrepresented in genetic studies. This glaring disparity has prompted urgent calls for the establishment of large-scale cohorts tailored to this demographic, essential for advancing the field of precision medicine. Addressing this critical need, the Taiwan Precision Medicine Initiative (TPMI) emerges as a groundbreaking effort spearheaded by Academia Sinica in partnership with sixteen leading medical centers across Taiwan.

The TPMI has succeeded in enlisting a staggering 565,390 participants, each consenting to provide DNA samples alongside granting researchers access to their electronic medical records (EMR). This dual consent enables a comprehensive integration of genetic data with clinical histories, creating a robust platform for both retrospective and prospective analyses. Notably, this enables longitudinal tracking of health outcomes, a pivotal feature that sets TPMI apart in studying disease progression and treatment efficacies over time.

One of the cornerstones of TPMI’s methodology is the use of population-optimized single nucleotide polymorphism (SNP) arrays designed specifically for individuals of Han Chinese ancestry. These arrays allow exhaustive genome-wide association studies (GWAS), which can identify genetic variants linked to disease susceptibility and drug response unique to this population. By deploying such customized genetic tools, TPMI ensures greater accuracy and relevance in its findings compared to generalized genomic arrays designed primarily for European ancestries.

Beyond GWAS, TPMI’s rich dataset supports phenome-wide association studies (PheWAS), a systematic approach to explore the relationship between genetic variants and a broad spectrum of phenotypes documented in EMRs. This multi-dimensional analysis pushes the boundaries, facilitating the discovery of novel genotype-phenotype correlations that can inform both diagnostics and therapeutic interventions unique to the Han Chinese population.

A third pillar of TPMI’s genetic research framework is the development and validation of polygenic risk scores (PRS). These scores aggregate the effects of multiple genetic loci to estimate an individual’s predisposition to common diseases such as diabetes, cardiovascular disease, and various cancers. By recalibrating PRS specifically for Han Chinese genetic architecture, TPMI enhances the predictive power and utility of these scores, thus pushing precision medicine closer to clinical practice in Taiwan and potentially across East Asia.

An innovative aspect of TPMI lies in the participants’ willingness to be recontacted. This unique feature fosters a dynamic research environment, allowing the cohort to be actively engaged in follow-up studies and clinical trials. Moreover, participants receive personalized genetic risk profiles, accompanied by tailored health management recommendations. This bidirectional communication model exemplifies forward-thinking participant engagement and promotes translational outcomes that benefit individual and public health.

The TPMI Data Access Platform (TDAP) operates as the centralized hub for securing and analyzing the vast troves of genomic and clinical data. This platform is not only designed with cutting-edge security protocols to protect participant confidentiality but also equipped with advanced computational tools that facilitate research collaborations. TDAP democratizes access for academic researchers, accelerating discoveries and ensuring that data are harnessed to their maximum potential.

TPMI’s establishment is particularly notable for merging genetic profiling with EMR data on an unprecedented scale for a non-European ancestry cohort. This expansive integration allows for rigorous validation of genetic risk prediction models across diverse clinical contexts and supports the conduction of clinical trials based on risk stratification. Such trials hold promise to revolutionize health management by shifting focus from reactive treatment to preventive care grounded in genetic risk.

Clinically, TPMI’s resource enables an unprecedented opportunity to examine pharmacogenetic responses among Han Chinese populations, a relatively understudied area resulting in suboptimal drug dosing and efficacy in this group. By elucidating genetic markers associated with drug metabolism and adverse reactions, TPMI paves the way toward safer, more effective personalized therapies.

From a policy perspective, findings derived from TPMI hold critical implications for shaping health care guidelines and resource allocation in Taiwan and potentially throughout East Asia. The initiative sets a compelling precedent for precision medicine strategies tailored to specific population genetics, highlighting the necessity of inclusive genomic research that embraces ethnic diversity.

With its scale, scope, and innovative design, the Taiwan Precision Medicine Initiative represents a landmark in global genomic research. It not only addresses the historical underrepresentation of Han Chinese individuals in genetic studies but also propels precision medicine into a new era where population-specific insights drive improvements in disease prevention, diagnosis, and therapeutic strategies.

In summary, TPMI stands as a model for how synergy between advanced genomics, comprehensive clinical data, and participant-centered approaches can transform medical research and health care delivery. As the cohort continues to grow and data accumulate, TPMI is poised to contribute seminal discoveries to the scientific community and reshape the global landscape of precision medicine.

Subject of Research:
The research focuses on creating and utilizing a large-scale, population-specific cohort of Han Chinese individuals to advance genetic studies, precision medicine applications, and health outcome predictions by integrating genome-wide data with electronic medical records.

Article Title:
The Taiwan Precision Medicine Initiative provides a cohort for large-scale studies.

Article References:
Yang, HC., Kwok, PY., Li, LH. et al. The Taiwan Precision Medicine Initiative provides a cohort for large-scale studies. Nature (2025). https://doi.org/10.1038/s41586-025-09680-x

Image Credits: AI Generated